A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)

Published:2010-03 Issue:3 Volume:5 Page:380-384
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Miller Antonius A.,Pang Herbert,Hodgson Lydia,Ramnath Nithya,Otterson Gregory A.,Kelley Michael J.,Kratzke Robert A.,Vokes Everett E.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

3. Small cell lung cancer: have we made any progress over the last 25 years?;Lally;Oncologist,2007

4. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

5. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan;Perez-Soler;J Clin Oncol,1996

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the EphA2 pathway: could it be the way for bone sarcomas?;Cell Communication and Signaling;2024-09-09

2. Unveiling the unique role of TSPAN7 across tumors: a pan-cancer study incorporating retrospective clinical research and bioinformatic analysis;Biology Direct;2024-08-22

3. KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling;ACS Omega;2022-09-01

4. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug;Acta Biochimica et Biophysica Sinica;2021-05-07

5. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer;Journal of Drug Targeting;2020-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3